Showing results (881-890 of 1,006) with videos related to

Sort By:
Pageof 101
Ejhaem|January 27, 2025
Characteristics of relapsed/refractory diffuse large B-cell lymphoma patients with durable responses to maveropepimut-S, pembrolizumab, and cyclophosphamide: Long-term follow-up from the SPiReL trialArjun Pandey, Kim Roos, Yidi Jiang, et al.
Ejhaem|January 27, 2025
Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in EnglandSally Moore, Laura Cornic, Christina-Jane Crossman-Barnes, et al.
Ejhaem|March 20, 2025
Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World AnalysisThomas Hueso, Grégory Lazarian, Paul Chauvet, et al.
Ejhaem|March 11, 2025
Lisocabtagene Maraleucel for Richter's Transformation-A Case SeriesCourtney J Smith, Anmol Goyal, Brian R Smith, et al.
Ejhaem|October 17, 2024
VEXAS without vacuoles: Linking genotype to phenotypeSara Zhukovsky, Anton Rets, Tawnie Braaten, et al.
Ejhaem|October 17, 2024
Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in EnglandChristopher P Fox, William Townsend, John G Gribben, et al.
Ejhaem|October 17, 2024
Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemiaNilesh Kapoor, Qiuhong Zhao, Andrew Stiff, et al.
Ejhaem|October 17, 2024
Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemiaIngrid Glimelius, Geffen Kleinstern, Dennis P Robinson, et al.
Ejhaem|October 17, 2024
Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experienceDario Melotti, Samir Asher, Ethan Troy-Barnes, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Pageof 101